

## **Supplementary Materials for**

# **1,3,4-Thiadiazoline–coumarin hybrid compounds containing D-glucose/D-galactose moieties: Synthesis and evaluation of their antiproliferative activity**

Vu Ngoc Toan <sup>a</sup>, Nguyen Dinh Thanh <sup>\*b</sup>, Nguyen Minh Tri <sup>a,b</sup>

<sup>a</sup> Department of Toxicological Chemistry and Radiation, Institute for Advanced Technology (Vietnam Academy of Military Science and Technology), 17 Hoang Sam, Cau Giay, Ha Noi, Viet Nam

<sup>b</sup> Faculty of Chemistry, VNU University of Science (Vietnam National University, Ha Noi), 19 Le Thanh Tong, Hoan Kiem, Ha Noi, Viet Nam

## **Table of Contents**


<b>1. Results of molecular docking study .....</b>	<b>3</b>
1.1. 2D interactions with EGFR (enzyme 3POZ) of selected compounds 9a,9c,9d,9f, and 9g (A–E) and of Sorafenib (F).....	3
1.2. 3D interactions with EGFR of selected compounds 9a,9c,9d,9f, and 9g (A–E) and of Sorafenib (F) .....	6
1.3. Alignments in binding pocket of EGFR (enzyme 3POZ) of selected compounds 9a,9c,9d,9f, and 9g (A–E) and of Sorafenib (F).....	9
1.4. 2D interactions with HER2 (enzyme 3CRD) of selected compounds 9a,9c,9d,9f, and 9g (A–E) and of Sorafenib (F).....	12
1.5. 3D interactions with HER2 of selected compounds 9a,9c,9d,9f, and 9g (A–E) and of Sorafenib (F) .....	15
1.6. Alignments in binding pocket HER2 (enzyme 3CRD) of selected compounds 9a,9c,9d,9f, and 9g (A–E) and of Sorafenib (F).....	18
<b>2. Spectra of synthesized compounds.....</b>	<b>21</b>
2.1. Spectra of 6- and 7- alkoxy-2-oxo-2H-chromene-4-carbaldehyde N-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)thiosemicarbazones (8a-g).....	21
(1) 6-Ethoxy-2-oxo-2H-chromene-4-carbaldehyde N-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)thiosemicarbazone ( <b>8a</b> ) .....	21
(2) 6-Butoxy-2-oxo-2H-chromene-4-carbaldehyde N-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)thiosemicarbazone ( <b>8b</b> ).....	22
(3) 6-Pentoxy-2-oxo-2H-chromene-4-carbaldehyde N-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)thiosemicarbazone ( <b>8c</b> ) .....	24
(4) 6-Isopentoxy-2-oxo-2H-chromene-4-carbaldehyde N-(2,3,4,6-tetra-O-acetyl-	

$\beta$ -D-glucopyranosyl)thiosemicarbazone ( <b>8d</b> ).....	25
(5) 7-Ethoxy-2-oxo-2H-chromene-4-carbaldehyde N-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-galactopyranosyl)thiosemicarbazone ( <b>8e</b> ) .....	27
(6) 7-Isobutoxy-2-oxo-2H-chromene-4-carbaldehyde N-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)thiosemicarbazone ( <b>8f</b> ) .....	28
(7) 7-Isopentoxy-2-oxo-2H-chromene-4-carbaldehyde N-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)thiosemicarbazone ( <b>8g</b> ).....	30
2.2. Spectra of synthesized 1,3,4-thiadiazoline–coumarin hybrid compounds (9a-g). .	32
(1) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-galactopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-6-ethoxycoumarin ( <b>9a</b> ).....	32
(2) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-6-butoxycoumarin ( <b>9b</b> ) .....	34
(3) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-6-pentoxycoumarin ( <b>9c</b> ) .....	36
(4) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-galactopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-6-ethoxycoumarin ( <b>9a</b> )4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-6-isopentoxycoumarin ( <b>9d</b> ) .....	37
(5) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-galactopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-7-ethoxycoumarin ( <b>9e</b> ) .....	39
(6) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-7-isobutoxycoumarin ( <b>9f</b> ).....	41
(7) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-7-isopentoxycoumarin ( <b>9g</b> ) .....	42


## 1. Results of molecular docking study

### 1.1. 2D interactions with EGFR (enzyme 3POZ) of selected compounds 9a,9c,9d,9f, and 9g (A–E) and of Sorafenib (F)


(A) Compound 9b (R = 6-O<sup>n</sup>C<sub>4</sub>H<sub>9</sub>)




(B) Compound 9c (R = 6-O<sup>n</sup>C<sub>5</sub>H<sub>11</sub>)




(C) Compound **9e** ( $R = 7\text{-OC}_2\text{H}_5$ )




(D) Compound **9f** ( $R = 7\text{-O}'\text{C}_4\text{H}_9$ )



(E) Compound **9g** ( $R = 7\text{-O}^i\text{C}_5\text{H}_{11}$ )




(F) Sorafenib



## 1.2. 3D interactions with EGFR of selected compounds 9a,9c,9d,9f, and 9g (A–E) and of Sorafenib (F)


(A) Compound **9b** ( $R = 6\text{-O}^n\text{C}_4\text{H}_9$ )




(B) Compound **9c** ( $R = 6\text{-O}^n\text{C}_5\text{H}_{11}$ )




(C) Compound **9e** ( $R = 7\text{-OC}_2\text{H}_5$ )




(D) Compound **9f** ( $R = 7\text{-O}^i\text{C}_4\text{H}_9$ )



(E) Compound **9g** ( $R = 7\text{-O}^i\text{C}_5\text{H}_{11}$ )




(F) Sorafenib




### 1.3. Alignments in binding pocket of EGFR (enzyme 3POZ) of selected compounds 9a,9c,9d,9f, and 9g (A–E) and of Sorafenib (F)


(A) Compound 9b (R = 6-O<sup>n</sup>C<sub>4</sub>H<sub>9</sub>)




(B) Compound 9c (R = 6-O<sup>n</sup>C<sub>5</sub>H<sub>11</sub>)




(C) Compound **9e** ( $R = 7\text{-OC}_2\text{H}_5$ )




(D) Compound **9f** ( $R = 7\text{-O}^i\text{C}_4\text{H}_9$ )



(E) Compound **9g** ( $R = 7\text{-O}^i\text{C}_5\text{H}_{11}$ )




(F) Sorafenib




#### 1.4. 2D interactions with HER2 (enzyme 3CRD) of selected compounds 9a,9c,9d,9f, and 9g (A–E) and of Sorafenib (F)


(A) Compound **9b** ( $R = 6\text{-O}''\text{C}_4\text{H}_9$ )




(B) Compound **9c** ( $R = 6\text{-O}''\text{C}_5\text{H}_{11}$ )




(C) Compound **9e** ( $R = 7\text{-OC}_2\text{H}_5$ )




(D) Compound **9f** ( $R = 7\text{-O}^i\text{C}_4\text{H}_9$ )



(E) Compound **9g** ( $R = 7\text{-O}^i\text{C}_5\text{H}_{11}$ )




(F) Sorafenib




### 1.5. 3D interactions with HER2 of selected compounds 9a,9c,9d,9f, and 9g (A–E) and of Sorafenib (F)


(A) Compound **9b** ( $R = 6\text{-O}''\text{C}_4\text{H}_9$ )




(B) Compound **9c** ( $R = 6\text{-O}''\text{C}_5\text{H}_{11}$ )




(C) Compound **9e** ( $R = 7\text{-OC}_2\text{H}_5$ )




(D) Compound **9f** ( $R = 7\text{-O}^{\prime}\text{C}_4\text{H}_9$ )



(E) Compound **9g** ( $R = 7\text{-O}^i\text{C}_5\text{H}_{11}$ )




(F) Sorafenib




**1.6. Alignments in binding pocket HER2 (enzyme 3CRD) of selected compounds 9a,9c,9d,9f, and 9g (A–E) and of Sorafenib (F)**


(A) Compound **9b** ( $R = 6\text{-O}^n\text{C}_4\text{H}_9$ )




(B) Compound **9c** ( $R = 6\text{-O}^n\text{C}_5\text{H}_{11}$ )




(C) Compound **9e** ( $R = 7\text{-OC}_2\text{H}_5$ )




(D) Compound **9f** ( $R = 7\text{-O}^i\text{C}_4\text{H}_9$ )



(E) Compound **9g** ( $R = 7\text{-O}^i\text{C}_5\text{H}_{11}$ )




(F) Sorafenib




## 2. Spectra of synthesized compounds


### 2.1. Spectra of 6- and 7- alkoxy-2-oxo-2*H*-chromene-4-carbaldehyde *N*-(2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-glucopyranosyl)thiosemicarbazones (8a-g)



(1) 6-Ethoxy-2-oxo-2*H*-chromene-4-carbaldehyde *N*-(2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-galactopyranosyl)thiosemicarbazone (8a)






(2) *6-Butoxy-2-oxo-2H-chromene-4-carbaldehyde N-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)thiosemicarbazone (8b)*







(3) 6-Pentoxy-2-oxo-2H-chromene-4-carbaldehyde N-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)thiosemicarbazone (**8c**)




\_200506135522 #416 RT: 4.82 AV: 1 NL: 1.34E5 T:  
ITMS + c ESI Full ms [50.00-2000.00]



(4) *6-Isopentoxy-2-oxo-2H-chromene-4-carbaldehyde N-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)thiosemicarbazone (8d)*




**Glu4Fo6IsoPentoxyCou-DMSO-C13CPD**




Tel: 844.38.253.053; Fax: 844.38.241.140 Mail: [Chem.vnu@.edu.vn](mailto:Chem.vnu@.edu.vn)  
C:\LTQ Orbitrap\..\5b\_200506135522



Sample name : 6OPr4MeCou Glc  
Mode: ESI, M+H

5/6/2020 2:10:35 PM





(5) 7-Ethoxy-2-oxo-2H-chromene-4-carbaldehyde N-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-galactopyranosyl)thiosemicarbazone (**8e**)







(6) 7-Isobutoxy-2-oxo-2H-chromene-4-carbaldehyde N-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)thiosemicarbazone (**8f**)







(7) *7-Isopentoxy-2-oxo-2H-chromene-4-carbaldehyde N-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)thiosemicarbazone (8g)*






**Analysis Info:**








## 2.2. Spectra of synthesized 1,3,4-thiadiazoline–coumarin hybrid compounds (9a-g)

(1) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-galactopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-6-ethoxycoumarin (9a)









(2) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-6-butoxycoumarin (**9b**)

**4For6BuGluCouAndehit-DMSO-1H**



**4For6BuGluCouAndehit-DMSO-C13CPD**



Lab: Materials chemistry, Faculty of Chemistry, HUS-VNU  
19 Le Thanh Tong, Hoan Kiem, Ha Noi

Tel: 844.38.253.053; Fax: 844.38.241.140 Mail: [Chem.vnu@edu.vn](mailto:Chem.vnu@edu.vn)


C:\LTQ Orbitrap\...\5b\_200506135523

Operator: Ms. Dao Thi Nhungh  
Mobile: 0948 119 043; Email: [daothinhungtn@yahoo.com](mailto:daothinhungtn@yahoo.com)



**Mass Spectrometer**  
**LTO Orbitrap XL™**


Sample name : Glc6OPr4MeCouThiadiaz

5/6/2020 2:11:35 PM Mode: ESI, M+H




(3) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-6-pentoxycoumarin (**9c**)






(4) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-galactopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-6-ethoxycoumarin (**9a**)  
(4) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-6-isopentoxycoumarin (**9d**)



### 4For6isoPenCouGluAndehit-DMSO-C13CPD



**Lab:** Materials chemistry, Faculty of Chemistry, HUS-VNU  
19 Le Thanh Tong, Hoan Kiem, Ha Noi

Tel: 844.38.253.053; Fax: 844.38.241.140 Mail: [Chem.vnu@.edu.vn](mailto:Chem.vnu@.edu.vn)


C:\LTQ Orbitrap\...5b\_200506135551

Operator: Ms. Dao Thi Nhung  
Mobile: 0948 119 043; Email: [daothinhungtn@yahoo.com](mailto:daothinhungtn@yahoo.com)


**Mass Spectrometer**  
**LTQ Orbitrap XL™**


Sample name : Glc6iOPn4ForCouThiadiaz

5/6/2020 4:10:35 PM Mode: ESI, M+H




(5) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-galactopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-7-ethoxycoumarin (**9e**)




**Analysis Info:**


C:\LTQ Orbitrap\...\\5b\_2005061343435622

546/2020 2:11:35 PM Mode: ESI, M+H




(6) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-7-isobutoxycoumarin (**9f**)






(7) 4-(3'-Acetyl-5'-(N-(2'',3'',4'',6''-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)acetamido-2'-methyl-2',3'-dihydro-1',3',4'-thiadiazol-2'-yl)-7-isopentoxycoumarin (9g)

**4For7isoPenCouGluAndehit-DMSO-1H**





Lab: Materials chemistry, Faculty of Chemistry, HUS-VNU

19 Le Thanh Tong, Hoan Kiem, Ha Noi

Tel: 844.38.253.053; Fax: 844.38.241.140 Mail: [Chem.vnu@edu.vn](mailto:Chem.vnu@edu.vn)

C:\LTQ Orbitrap\...\5b\_200506135521

Operator: Ms. Dao Thi Nhun

Mobile: 0948 119 043; Email: [daothinhungtn@yahoo.com](mailto:daothinhungtn@yahoo.com)

**Mass Spectrometer**

**LTQ Orbitrap XL™**

Sample name : Glc7O iPn4ForCouThiadiaz

16/9/2020 9:25 AM Mode: ESI, M+H

